Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.50 |
| ▸ | MAPT | P10636 | 1/20 | 0.45 |
| ▸ | FPR3 | P25089 | 1/20 | 0.40 |
| ▸ | FPR2 | P25090 | 1/20 | 0.40 |
| ▸ | LMNA | P02545 | 1/20 | 0.40 |
| ▸ | GBA1 | P04062 | 1/20 | 0.38 |
| ▸ | CXCR4 | P61073 | 1/20 | 0.38 |
| ▸ | MEN1 | O00255 | 1/20 | 0.37 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.37 |
| ▸ | LSS | P48449 | 1/20 | 0.37 |
| ▸ | HRH1 | P35367 | 1/20 | 0.36 |
| ▸ | TP53 | P04637 | 1/20 | 0.36 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL439740 | 0.95 | HRH3 (0.56) | HRH3MAPTFPR3FPR2LMNA | |
| SCHEMBL38662815 | 0.93 | HRH3 (0.61) | HRH3MAPTFPR3FPR2LMNA | |
| SCHEMBL21016238 | 0.93 | HRH3 (0.61) | HRH3MAPTFPR3FPR2LMNA | |
| SCHEMBL441058 | 0.93 | HRH3 (0.61) | HRH3MAPTFPR3FPR2MEN1 | |
| SCHEMBL441042 | 0.93 | HRH3 (0.46) | HRH3MAPTFPR3FPR2LMNA | |
| SCHEMBL7866253 | 0.91 | HRH3 (0.65) | HRH3MAPTFPR3FPR2CXCR4 | |
| SCHEMBL6246899 | 0.91 | HRH3 (0.65) | HRH3MAPTFPR3FPR2CXCR4 | |
| Bromide SCHEMBL15941761 | 0.91 | HRH3 (0.58) | HRH3MAPTFPR3FPR2LMNA | |
| SCHEMBL10778023 | 0.91 | HRH3 (0.65) | HRH3MAPTFPR3FPR2CXCR4 | |
| SCHEMBL1810789 | 0.88 | HRH3 (0.46) | HRH3LMNAGBA1TP53SMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 48 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11827641-B2 | Toll-like receptor antagonist compounds and methods of use | DYNAVAX TECHNOLOGIES CORPORATION (US) | 2023-11-28 | — | — | US | disclosed |
| EP-3519393-B1 | SUBSTITUTED FUSED BI- OR TRI- HETEROCYCLIC COMPOUNDS AS EHMT2 INHIBITORS | EPIZYME INC (US) | 2022-05-18 | — | — | EP | disclosed |
| US-20170334841-A1 | TETRACYCLINE COMPOUNDS | TETRAPHASE PHARMACEUTICALS, INC. | 2017-11-23 | — | — | US | disclosed |
| US-9616099-B2 | Cyclosporin analogues for preventing or treating hepatitis C infection | ENANTA PHARMACEUTICALS, INC. (US) | 2017-04-11 | — | — | US | disclosed |
| US-9616099-B2 | Cyclosporin analogues for preventing or treating hepatitis C infection | ENANTA PHARMACEUTICALS, INC. (US) | 2017-04-11 | — | — | US | disclosed |
| US-9603895-B2 | Cyclosporin analogues for preventing or treating hepatitis C infection | ENANTA PHARMACEUTICALS, INC. (US) | 2017-03-28 | — | — | US | disclosed |
| US-9603895-B2 | Cyclosporin analogues for preventing or treating hepatitis C infection | ENANTA PHARMACEUTICALS, INC. (US) | 2017-03-28 | — | — | US | disclosed |
| US-20160136233-A1 | NOVEL CYCLOSPORIN ANALOGUES FOR PREVENTING OR TREATING HEPATITIS C INFECTION | ENANTA PHARM INC (US) | 2016-05-19 | — | — | US | disclosed |
| US-20160136233-A1 | NOVEL CYCLOSPORIN ANALOGUES FOR PREVENTING OR TREATING HEPATITIS C INFECTION | ENANTA PHARM INC (US) | 2016-05-19 | — | — | US | disclosed |
| US-9290503-B2 | Tricyclic compound derivatives useful in the treatment of neoplastic diseases, inflammatory disorders and immunomodulatory disorders | CHEMBRIDGE CORPORATION (US) | 2016-03-22 | — | — | US | disclosed |
| US-20100267757-A1 | AMINOTHIAZOLES AND THEIR USES | NOVARTIS AG (CH) | 2010-10-21 | — | — | US | disclosed |
| US-20100196316-A1 | CYCLOSPORIN ANALOGUES FOR PREVENTING OR TREATING HEPATITIS C INFECTION | ENANTA PHARMACEUTICALS, INC. | 2010-08-05 | — | — | US | disclosed |
| US-20100196316-A1 | CYCLOSPORIN ANALOGUES FOR PREVENTING OR TREATING HEPATITIS C INFECTION | ENANTA PHARMACEUTICALS, INC. | 2010-08-05 | — | — | US | disclosed |
| US-20090186830-A1 | MACROCYCLES AND THEIR USES | NOVARTIS AG (CH) | 2009-07-23 | — | — | US | disclosed |
| US-20090186830-A1 | MACROCYCLES AND THEIR USES | NOVARTIS AG (CH) | 2009-07-23 | — | — | US | disclosed |
| US-20080221142-A1 | useful in interfering with the life cycle of bacteria and in treating or preventing a bacterial infection | NOVARTIS AG (CH) | 2008-09-11 | — | — | US | disclosed |
| US-20080171769-A1 | Tricyclic compound derivatives useful in the treatment of neoplastic diseases, inflammatory disorders and immunomodulatory disorders | CHEMBRIDGE CORPORATION | 2008-07-17 | — | — | US | disclosed |
| US-20080171769-A1 | Tricyclic compound derivatives useful in the treatment of neoplastic diseases, inflammatory disorders and immunomodulatory disorders | CHEMBRIDGE CORPORATION | 2008-07-17 | — | — | US | disclosed |
| US-20080161281-A1 | Amino-Substituted Tricyclic Derivatives and Methods of Use | ABBOTT LABORATORIES (US) | 2008-07-03 | — | — | US | disclosed |
| US-7365193-B2 | Amino-substituted tricyclic derivatives and methods of use | ABBOTT LABORATORIES (US) | 2008-04-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100267757-A1 | AMINOTHIAZOLES AND THEIR USES | ABAT, AADAT, GOT2 | HRH3 3180/4885MAPT 380/4885FPR3 1083/4885 |
| US-20080221142-A1 | useful in interfering with the life cycle of bacteria and in treating or preventing a bacterial infection | LPO, PCNA, BPGM | HRH3 3731/4885MAPT 4316/4885FPR3 856/4885 |
| US-11827641-B2 | Toll-like receptor antagonist compounds and methods of use | TLR7, TLR9, TLR1 | HRH3 355/4885MAPT 4108/4885FPR3 64/4885 |
| US-20160136233-A1 | NOVEL CYCLOSPORIN ANALOGUES FOR PREVENTING OR TREATING HEPATITIS C INFECTION | HAVCR2, CHP1, MAVS | HRH3 4276/4885MAPT 4138/4885FPR3 598/4885 |
| US-20100196316-A1 | CYCLOSPORIN ANALOGUES FOR PREVENTING OR TREATING HEPATITIS C INFECTION | HAVCR2, CHP1, PTPRC | HRH3 4009/4885MAPT 3971/4885FPR3 486/4885 |
| US-20090186830-A1 | MACROCYCLES AND THEIR USES | CYP11B2, OAT, CYP27A1 | HRH3 3885/4885MAPT 2470/4885FPR3 1310/4885 |
| US-20080171769-A1 | Tricyclic compound derivatives useful in the treatment of neoplastic diseases, inflammatory disorders and immunomodulatory disorders | MALT1, TPMT, TSLP | HRH3 866/4885MAPT 63/4885FPR3 2429/4885 |
| US-20080161281-A1 | Amino-Substituted Tricyclic Derivatives and Methods of Use | CHRNA1, CHRM1, CHRNB1 | HRH3 321/4885MAPT 3318/4885FPR3 486/4885 |
| US-20170334841-A1 | TETRACYCLINE COMPOUNDS | TUBB, TUBA1A, TUBA1C | HRH3 4238/4885MAPT 93/4885FPR3 4446/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.